Abstract:Abstract Introduction Although there is evidence supporting high comorbidity rates among insomnia, anxiety, and depression, the temporal relationship among them is less clear. Prior research supports that the onset of depression is often preceded by symptoms of anxiety and insomnia, but the current study is the first to look at the temporal relationship among all three symptoms in an adult sample representative of the general population. Determining the temporal progression of these problems is important for prevention and intervention efforts, in that early treatment for insomnia and anxiety may reduce the risk of developing depression. Methods 2,666 adult participants (Mage = 47.0, 79.0% female, 84.1% white) were recruited for an online study on health, resulting in a nationally representative sample. Well-validated instruments were used to measure symptoms of depression (CES-D), anxiety (STAI), and insomnia (ISI). Data was collected via Qualtrics surveys administered online at two time points (i.e., baseline and follow-up), with assessments conducted twice daily for two weeks in the morning and evening. Auto-regressive cross-lagged models were used to provide the best representation for how these data were collected, and allowed for temporal ordering at every pathway by examining the longitudinal relationship between each variable. Results Auto-regressive cross-lagged models revealed an indirect effect of anxiety symptoms on depression symptoms through insomnia symptoms. Tests of indirect effect were performed in two ways, using both insomnia T1 and insomnia T2 to provide temporal ordering between all three variables. The indirect effect of anxiety T1 on depression T2 through insomnia T1 was significant (β = 0.253, p < 0.001). The indirect effect of anxiety T1 on depression T2 through insomnia T2 was also significant (β = 0.265, p < 0.001). The almost-identical values for the two tests of indirect effect provide support for the presence of the temporal relationship between these three variables. Conclusion Results support the theory that insomnia may be one mechanism by which individuals with anxiety are at greater risk for developing depression. This is the first study to empirically evaluate a model in which insomnia symptoms explain the indirect effect of anxiety symptoms on depression symptoms in adults. Support (if any) Vargas: K23HL141581
What problem does this paper attempt to address?
The paper primarily explores the longitudinal relationships between insomnia, anxiety, and depressive symptoms, and examines the effects of the drug Suvorexant on depressive and withdrawal symptoms during opioid withdrawal.
### Part 1: The Relationship Between Insomnia, Anxiety, and Depressive Symptoms
- **Research Background**: Although there is evidence suggesting a high comorbidity rate between insomnia, anxiety, and depressive symptoms, the temporal relationship between these symptoms remains unclear. Previous studies support the view that depressive symptoms are often preceded by anxiety and insomnia symptoms.
- **Research Methods**: The study recruited 2,666 adult participants (average age 47 years, 79% female, 84.1% white) and collected data through online surveys. Valid tools were used to measure depressive symptoms (CES-D), anxiety symptoms (STAI), and insomnia symptoms (ISI). Data were collected via Qualtrics online questionnaires at two time points: baseline and follow-up, with twice-daily assessments over two weeks at each time point. An autoregressive cross-lagged model was used to analyze the data.
- **Research Results**: The results showed that anxiety symptoms indirectly influenced depressive symptoms through insomnia symptoms. Specifically, anxiety symptoms at T1 significantly indirectly influenced depressive symptoms at T2 through insomnia symptoms at T1 (β = 0.253, p < 0.001) and also significantly indirectly influenced depressive symptoms at T2 through insomnia symptoms at T2 (β = 0.265, p < 0.001).
- **Conclusion**: The study supports that insomnia may be a mechanism by which anxiety patients are more likely to develop depression. This is the first empirical study to validate the model that anxiety symptoms indirectly influence depressive symptoms through insomnia symptoms.
### Part 2: The Effects of Suvorexant on Symptoms During Opioid Withdrawal
- **Research Background**: Opioid withdrawal can exacerbate depressive symptoms and sleep disturbances. Previous studies have shown that Suvorexant can alleviate sleep disturbances during withdrawal, but it is unclear whether these changes also improve depressive or withdrawal symptoms.
- **Research Methods**: The study recruited 38 patients with opioid use disorder (age range 21-63 years, 87% male, 45% white) for an 11-night withdrawal process (including 3 nights of stabilization, 4 nights of buprenorphine tapering, and 3 nights post-buprenorphine tapering). Participants were randomly assigned to the Suvorexant group (20mg or 40mg) or the placebo group, and sleep EEG data were collected. Linear mixed-effects models were used to test the association between changes in sleep EEG band power and depressive symptoms and withdrawal severity.
- **Research Results**: Throughout the 11-night withdrawal process, all groups observed a decrease in oscillatory δ power and increases in β, α, and σ power. In the Suvorexant group, a decrease in δ power was associated with a reduction in depressive symptoms (20mg: β= -190.90, p = 0.99; 40mg: β= -433.33, p < 0.001) and a reduction in withdrawal severity (20mg: β= -215.55, p = 0.006; 40mg: β= -192.64, p < 0.001). An increase in σ power was also associated with a reduction in withdrawal severity (20mg: β= -357.84, p = 0.004; 40mg: β= -906.35, p < 0.001). In the placebo group, a decrease in δ power and σ power was associated with a reduction in depressive symptoms.
- **Conclusion**: Suvorexant can improve depressive symptoms and withdrawal severity during opioid withdrawal, which may be related to changes in sleep EEG band power.
Overall, these two studies respectively explore the temporal relationships between insomnia, anxiety, and depressive symptoms, and the effects of Suvorexant on symptoms during opioid withdrawal, providing important theoretical basis for clinical interventions.